» Articles » PMID: 32373531

Texture Analysis of Breast DCE-MRI Based on Intratumoral Subregions for Predicting HER2 2+ Status

Overview
Journal Front Oncol
Specialty Oncology
Date 2020 May 7
PMID 32373531
Citations 7
Authors
Affiliations
Soon will be listed here.
Abstract

Breast tumor heterogeneity is related to risk factors that lead to aggressive tumor growth; however, such heterogeneity has not been thoroughly investigated. To evaluate the performance of texture features extracted from heterogeneity subregions on subtraction MRI images for identifying human epidermal growth factor receptor 2 (HER2) 2+ status of breast cancers. Seventy-six patients with HER2 2+ breast cancer who underwent dynamic contrast-enhanced magnetic resonance imaging were enrolled, including 42 HER2 positive and 34 negative cases confirmed by fluorescence hybridization. The lesion area was delineated semi-automatically on the subtraction MRI images at the second, fourth, and sixth phases (P-1, P-2, and P-3). A regionalization method was used to segment the lesion area into three subregions (rapid, medium, and slow) according to peak arrival time of the contrast agent. We extracted 488 texture features from the whole lesion area and three subregions independently. Wrapper, least absolute shrinkage and selection operator (LASSO), and stepwise methods were used to identify the optimal feature subsets. Univariate analysis was performed as well as support vector machine (SVM) with a leave-one-out-based cross-validation method. The area under the receiver operating characteristic curve (AUC) was calculated to evaluate the performance of the classifiers. In univariate analysis, the variance from medium subregion at P-2 was the best-performing feature for distinguishing HER2 2+ status (AUC = 0.836); for the whole lesion region, the variance at P-2 achieved the best performance (AUC = 0.798). There was no significant difference between the two methods ( = 0.271). In the machine learning with SVM, the best performance (AUC = 0.929) was achieved with LASSO from rapid subregion at P-2; for the whole region, the highest AUC value was 0.847 obtained at P-2 with LASSO. The difference was significant between the two methods ( = 0.021). The texture analysis of heterogeneity subregions based on intratumoral regionalization method showed potential value for recognizing HER2 2+ status in breast cancer.

Citing Articles

Whole tumour- and subregion-based radiomics of contrast-enhanced mammography in differentiating HER2 expression status of invasive breast cancers: A double-centre pilot study.

Wang S, Wang T, Guo S, Zhu S, Chen R, Zheng J Br J Cancer. 2024; 131(10):1613-1622.

PMID: 39379571 PMC: 11554679. DOI: 10.1038/s41416-024-02871-9.


Radiomics Machine Learning Analysis of Clear Cell Renal Cell Carcinoma for Tumour Grade Prediction Based on Intra-Tumoural Sub-Region Heterogeneity.

Alhussaini A, Douglas Steele J, Jawli A, Nabi G Cancers (Basel). 2024; 16(8).

PMID: 38672536 PMC: 11048006. DOI: 10.3390/cancers16081454.


Deconvolution-Based Pharmacokinetic Analysis to Improve the Prediction of Pathological Information of Breast Cancer.

Zhang L, Fan M, Li L J Imaging Inform Med. 2024; 37(1):13-24.

PMID: 38343210 PMC: 10976965. DOI: 10.1007/s10278-023-00915-9.


Dynamic contrast-enhanced magnetic resonance imaging radiomics analysis based on intratumoral subregions for predicting luminal and nonluminal breast cancer.

Feng S, Yin J Quant Imaging Med Surg. 2023; 13(10):6735-6749.

PMID: 37869317 PMC: 10585575. DOI: 10.21037/qims-22-1073.


The use of radiomics in magnetic resonance imaging for the pre-treatment characterisation of breast cancers: A scoping review.

Campana A, Gandomkar Z, Giannotti N, Reed W J Med Radiat Sci. 2023; 70(4):462-478.

PMID: 37534540 PMC: 10715343. DOI: 10.1002/jmrs.709.


References
1.
Chang R, Chen H, Chang Y, Huang C, Chen J, Lo C . Quantification of breast tumor heterogeneity for ER status, HER2 status, and TN molecular subtype evaluation on DCE-MRI. Magn Reson Imaging. 2016; 34(6):809-819. DOI: 10.1016/j.mri.2016.03.001. View

2.
van Vuuren R, Visagie M, Theron A, Joubert A . Antimitotic drugs in the treatment of cancer. Cancer Chemother Pharmacol. 2015; 76(6):1101-12. PMC: 4648954. DOI: 10.1007/s00280-015-2903-8. View

3.
Yang X, Knopp M . Quantifying tumor vascular heterogeneity with dynamic contrast-enhanced magnetic resonance imaging: a review. J Biomed Biotechnol. 2011; 2011:732848. PMC: 3085501. DOI: 10.1155/2011/732848. View

4.
Mittendorf E, Wu Y, Scaltriti M, Meric-Bernstam F, Hunt K, Dawood S . Loss of HER2 amplification following trastuzumab-based neoadjuvant systemic therapy and survival outcomes. Clin Cancer Res. 2009; 15(23):7381-8. PMC: 2788123. DOI: 10.1158/1078-0432.CCR-09-1735. View

5.
Hollingsworth M, Swanson B . Mucins in cancer: protection and control of the cell surface. Nat Rev Cancer. 2003; 4(1):45-60. DOI: 10.1038/nrc1251. View